AR077460A1 - Uso de la combinacion de teriflunomida e interferon beta para el tratamiento de la esclerosis multiple - Google Patents

Uso de la combinacion de teriflunomida e interferon beta para el tratamiento de la esclerosis multiple

Info

Publication number
AR077460A1
AR077460A1 ARP100102476A ARP100102476A AR077460A1 AR 077460 A1 AR077460 A1 AR 077460A1 AR P100102476 A ARP100102476 A AR P100102476A AR P100102476 A ARP100102476 A AR P100102476A AR 077460 A1 AR077460 A1 AR 077460A1
Authority
AR
Argentina
Prior art keywords
teriflunomide
multiple sclerosis
interferon beta
treatment
combination
Prior art date
Application number
ARP100102476A
Other languages
English (en)
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41283539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077460(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of AR077460A1 publication Critical patent/AR077460A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Un método para tratar la forma relapsante-remitente de la esclerosis multiple, en un paciente que lo necesita, que comprende administrar al paciente aproximadamente 7 mg o aproximadamente 14 mg de teriflunomida, y una cantidad farmacéuticamente eficaz de interferon beta-1a o 1b.
ARP100102476A 2009-07-10 2010-07-08 Uso de la combinacion de teriflunomida e interferon beta para el tratamiento de la esclerosis multiple AR077460A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09305669A EP2277515A1 (en) 2009-07-10 2009-07-10 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
US22534209P 2009-07-14 2009-07-14
US28614809P 2009-12-14 2009-12-14
US35095710P 2010-06-03 2010-06-03

Publications (1)

Publication Number Publication Date
AR077460A1 true AR077460A1 (es) 2011-08-31

Family

ID=41283539

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102476A AR077460A1 (es) 2009-07-10 2010-07-08 Uso de la combinacion de teriflunomida e interferon beta para el tratamiento de la esclerosis multiple

Country Status (20)

Country Link
US (2) US20120107277A1 (es)
EP (2) EP2277515A1 (es)
JP (1) JP2012532881A (es)
KR (1) KR20120050976A (es)
CN (1) CN102470116A (es)
AR (1) AR077460A1 (es)
AU (1) AU2010271467A1 (es)
BR (1) BR112012000490A2 (es)
CA (1) CA2767711A1 (es)
CL (1) CL2012000062A1 (es)
CO (1) CO6491023A2 (es)
IL (1) IL217434A0 (es)
MA (1) MA33515B1 (es)
MX (1) MX2012000458A (es)
RU (1) RU2012104666A (es)
SG (1) SG177544A1 (es)
TW (1) TW201106945A (es)
UY (1) UY32781A (es)
WO (1) WO2011005907A1 (es)
ZA (1) ZA201108340B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3863628B1 (en) * 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
SI1381356T1 (sl) * 2001-04-05 2008-12-31 Aventis Pharma Inc Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze
RU2007118691A (ru) * 2004-10-19 2008-11-27 Авентис Фармасьютикалз Инк. (Us) Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника

Also Published As

Publication number Publication date
MA33515B1 (fr) 2012-08-01
KR20120050976A (ko) 2012-05-21
US20130156735A1 (en) 2013-06-20
JP2012532881A (ja) 2012-12-20
CA2767711A1 (en) 2011-01-13
MX2012000458A (es) 2012-01-27
TW201106945A (en) 2011-03-01
CO6491023A2 (es) 2012-07-31
WO2011005907A1 (en) 2011-01-13
IL217434A0 (en) 2012-02-29
SG177544A1 (en) 2012-03-29
CN102470116A (zh) 2012-05-23
BR112012000490A2 (pt) 2016-02-16
EP2451449A1 (en) 2012-05-16
AU2010271467A1 (en) 2012-02-02
RU2012104666A (ru) 2013-08-20
UY32781A (es) 2011-02-28
ZA201108340B (en) 2012-07-25
CL2012000062A1 (es) 2012-10-05
EP2451449B1 (en) 2014-05-07
US20120107277A1 (en) 2012-05-03
EP2277515A1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR061122A1 (es) Regimen de cladribina para tratar la escleorosis multiple
DOP2014000067A (es) Tratamiento combinado (por ejemplo con abt-072 o abt-333) de agentes antivirales de acción directa (daas) para uso en el tratamiento de hcv
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
CL2008003901A1 (es) Uso de un inhibidor de hedgehog para extender la sobrevida libre de recidiva en un paciente con cancer, que se encuentra en quimioterapia o ha sido tratado previamente con quimioterapia.
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
CR11418A (es) Trans-clomifeno para el sindrome metabolico
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
CL2012000586A1 (es) Uso de al menos 20 mg de un aerosol de una solucion que comprende levofloxacina u ofloxacina y un cation bivalente o trivalente, para el tratamiento de una infeccion pulmonar en un paciente con fibrosis quistica.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
UY31826A (es) Compuesto peptídico y su uso
ES2421407T3 (es) Agente y composición para la curación de heridas

Legal Events

Date Code Title Description
FB Suspension of granting procedure